Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.57 |
| ▸ | ACVR1B | P36896 | 15/20 | 0.57 |
| ▸ | ACVRL1 | P37023 | 11/20 | 0.57 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16879186 | 0.87 | TGFBR1 (0.72) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL16879305 | 0.84 | TGFBR1 (0.75) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL16879671 | 0.83 | TGFBR1 (0.67) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL16879398 | 0.82 | TGFBR1 (0.76) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL16879670 | 0.82 | TGFBR1 (0.76) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL16879709 | 0.79 | TGFBR1 (0.56) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL16879511 | 0.77 | TGFBR1 (0.55) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL16879626 | 0.76 | TGFBR1 (0.76) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL16888498 | 0.75 | TGFBR1 (0.56) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL18219801 | 0.75 | TGFBR1 (0.68) | TGFBR1ACVR1BACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3089971-B1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200071296-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2020-03-05 | — | — | US | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-10030004-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160326137-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2016-11-10 | — | — | US | disclosed |
| EP-3089971-A1 | COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015103355-A1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000847-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885 |
| US-10030004-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885 |
| US-20160326137-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885 |
| US-20200071296-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885 |
| US-11053216-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885 |
| US-20180208577-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885ACVR1B 150/4885ACVRL1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.